Key result
Implantable cardioverter defibrillators and antiarrhythmic therapies are promising for managing life-threatening arrhythmias and reducing sudden cardiac death risk in patients with heart failure.
Population
Patients with heart failure experiencing or at risk for arrhythmias
Design
Review
Authors
Loading...
May support ICD plus antiarrhythmic use in HF; leaves open need for randomized confirmation before practice change.
This review highlights the mechanisms of arrhythmogenesis in heart failure and emphasizes the critical role of implantable cardioverter defibrillators, often combined with antiarrhythmic drugs, for preventing sudden cardiac death.
Eckardt et al. (2000) conducted a review in Heart failure and arrhythmias. Implantable cardioverter defibrillator (ICD) and antiarrhythmic therapy was evaluated. Implantable cardioverter defibrillators and antiarrhythmic therapies are promising for managing life-threatening arrhythmias and reducing sudden cardiac death risk in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: